<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="add16684" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">ADD</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11638526</article-id><article-id pub-id-type="pmcid-ver">PMC11638526.1</article-id><article-id pub-id-type="pmcaid">11638526</article-id><article-id pub-id-type="pmcaiid">11638526</article-id><article-id pub-id-type="pmid">39397274</article-id><article-id pub-id-type="doi">10.1111/add.16684</article-id><article-id pub-id-type="publisher-id">ADD16684</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Report</subject></subj-group></article-categories><title-group><article-title>Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient&#8208; and prescriber&#8208;level characteristics in Massachusetts, USA</article-title><alt-title alt-title-type="right-running-head">BUPRENORPHINE TREATMENT AND PATIENT OUTCOMES</alt-title><alt-title alt-title-type="left-running-head">Young et al.</alt-title></title-group><contrib-group><contrib id="add16684-cr-0001" contrib-type="author"><name name-style="western"><surname>Young</surname><given-names initials="GJ">Gary J.</given-names></name><xref rid="add16684-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="add16684-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="add16684-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="add16684-cr-0002" contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="T">Tianjie</given-names></name><xref rid="add16684-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="add16684-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="add16684-cr-0003" contrib-type="author"><name name-style="western"><surname>Hasan</surname><given-names initials="MM">Md Mahmudul</given-names></name><xref rid="add16684-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="add16684-cr-0004" contrib-type="author"><name name-style="western"><surname>Alinezhad</surname><given-names initials="F">Farbod</given-names></name><xref rid="add16684-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="add16684-cr-0005" contrib-type="author"><name name-style="western"><surname>Young</surname><given-names initials="LD">Leonard D.</given-names></name><xref rid="add16684-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="add16684-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Noor&#8208;E&#8208;Alam</surname><given-names initials="M">Md.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5353-9710</contrib-id><xref rid="add16684-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="add16684-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>mnalam@neu.edu</email></address></contrib></contrib-group><aff id="add16684-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Center for Health Policy and Healthcare Research</named-content>
<institution>Northeastern University</institution>
<city>Boston</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><aff id="add16684-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Bouve College of Health Sciences</named-content>
<institution>Northeastern University</institution>
<city>Boston</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><aff id="add16684-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">D'Amore&#8208;McKim School of Business</named-content>
<institution>Northeastern University</institution>
<city>Boston</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><aff id="add16684-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Mechanical and Industrial Engineering</named-content>
<institution>Northeastern University</institution>
<city>Boston</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><aff id="add16684-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Information Systems and Operations Management, Warrington College of Business and Department of Pharmaceutical Outcomes and Policy, School of Pharmacy</named-content>
<institution>University of Florida</institution>
<city>Gainesville</city>
<named-content content-type="country-part">FL</named-content>
<country country="US">USA</country>
</aff><aff id="add16684-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Prescription Monitoring Program</named-content>
<institution>Massachusetts Department of Public Health</institution>
<city>Boston</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Md. Noor&#8208;E&#8208;Alam, Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA, USA.<break/>
Email: <email>mnalam@neu.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><volume>120</volume><issue seq="170">1</issue><issue-id pub-id-type="pmc-issue-id">476986</issue-id><issue-id pub-id-type="doi">10.1111/add.v120.1</issue-id><fpage>152</fpage><lpage>163</lpage><history><date date-type="received"><day>13</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>14</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-17 15:25:14.450"><day>17</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Addiction</italic> published by John Wiley &amp; Sons Ltd on behalf of Society for the Study of Addiction.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ADD-120-152.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ADD-120-152.pdf"/><abstract><title>Abstract</title><sec id="add16684-sec-0001"><title>Background and Aims</title><p>Opioid use disorder (OUD) is treatable with buprenorphine/naloxone (buprenorphine), but many patients discontinue treatment prematurely. The aim of this study was to assess the influence of patient&#8208; and prescriber&#8208;level characteristics relative to several patient outcomes following the initiation of buprenorphine treatment for OUD.</p></sec><sec id="add16684-sec-0002"><title>Design</title><p>This was a retrospective observational investigation. We used the Public Health Data Warehouse from the Massachusetts Department of Public Health to construct a sample of patients who initiated buprenorphine treatment between 2015 and 2019. We attributed each patient to a prescriber based on information from prescription claims. We used multilevel models to assess the influence of patient&#8208; and prescriber&#8208;level characteristics on each outcome.</p></sec><sec id="add16684-sec-0003"><title>Setting</title><p>Massachusetts, USA.</p></sec><sec id="add16684-sec-0004"><title>Participants</title><p>The study cohort comprised 37&#8201;955 unique patients and 2146 prescribers. Among patients, 64.6% were male, 52.6% were under the age of 35 and 82.2% were White, non&#8208;Hispanic. For insurance coverage, 72.1% had Medicaid.</p></sec><sec id="add16684-sec-0005"><title>Measurements</title><p>The outcome measures were poor medication continuity, treatment discontinuation and opioid overdose, all assessed within a 12&#8208;month follow&#8208;up period that began with a focal prescription for buprenorphine. Each patient had a single follow&#8208;up period. Poor medication continuity was defined as medication gaps totaling more than 7&#160;days during the initial 180&#8201;days of buprenorphine treatment and treatment discontinuation was defined as having a medication gap for 2 consecutive months within the 12&#8208;month follow&#8208;up period.</p></sec><sec id="add16684-sec-0006"><title>Findings</title><p>The patient&#8208;level rates for poor medication continuity, treatment discontinuation and opioid overdose were 59.7% [95% confidence interval (CI) = 59.2&#8211;60.2], 57.4% (95% CI = 56.9&#8211;57.9) and 10.3% (95% CI = 10.0&#8211;10.6), respectively, with 1.1% (95% CI = 1.0&#8211;1.2) experiencing a fatal opioid overdose. At the patient level, after adjustment for covariates, adverse outcomes were associated with race/ethnicity as both Black, non&#8208;Hispanic and Hispanic patients had worse outcomes than did White, non&#8208;Hispanic patients (Black, non&#8208;Hispanic &#8208;&#8208; poor continuity: 1.50, 95% CI = 1.34&#8211;1.68; discontinuation: 1.44, 95% CI = 1.30&#8211;1.60; Hispanic &#8208;&#8208; poor continuity: 1.21, 95% CI = 1.12&#8211;1.31; discontinuation: 1.38, 95% CI = 1.28&#8211;1.48). Patients with insurance coverage through Medicaid also had worse outcomes than those with commercial insurance (poor continuity: 1.18, 95% CI = 1.11&#8211;1.26; discontinuation: 1.09, 95% CI = 1.03&#8211;1.16; overdose: 1.98, 95% CI = 1.75&#8211;2.23). Pre&#8208;treatment mental health conditions and other types of chronic illness were also associated with worse outcomes (History of mental health conditions &#8208;&#8208; poor continuity: 1.11, 95% CI = 1.06&#8211;1.17; discontinuation: 1.05, CI = 1.01&#8211;1.10; overdose: 1.47, 95% CI = 1.36&#8211;1.60; Chronic health conditions &#8208;&#8208; poor continuity: 1.15, 95% CI = 1.05&#8211;1.27; discontinuation: 1.15, 95% CI = 1.05&#8211;1.26; overdose: 1.83, 95% CI = 1.60&#8211;2.10; History of substance use disorder other than for opioids &#8208;&#8208; poor continuity: 1.54, 95% CI = 1.46&#8211;1.62; discontinuation: 1.54, 95% CI = 1.47&#8211;1.62; overdose: 1.93, 95% CI = 1.80&#8211;2.07). At the prescriber level, after adjustments for covariates, adverse outcomes were associated with clinical training, as primary care physicians had higher rates of adverse outcomes than psychiatrists (poor continuity: 1.12, 95% CI = 1.02&#8211;1.23; discontinuation: 1.04, 95% CI = 1.01&#8211;1.09). A larger prescriber panel size, based on number of patients being prescribed buprenorphine, was also associated with higher rates of adverse outcomes (poor continuity: 1.36, 95% CI = 1.27&#8211;1.46; discontinuation: 1.21, 95% CI = 1.14&#8211;1.28; overdose: 1.10, 95% CI = 1.01&#8211;1.19). Between 9% and 15% of the variation among patients for the outcomes was accounted for at the prescriber level.</p></sec><sec id="add16684-sec-0007"><title>Conclusions</title><p>Patient&#8208; and prescriber&#8208;level characteristics appear to be associated with patient outcomes following buprenorphine treatment for opioid use disorder. In particular, patients' race/ethnicity and insurance coverage appear to be associated with substantial disparities in outcomes, and prescriber characteristics appear to be most closely associated with medication continuity during early treatment.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="add16684-kwd-0001">buprenorphine</kwd><kwd id="add16684-kwd-0002">multi&#8208;level models</kwd><kwd id="add16684-kwd-0003">opioid use disorder</kwd><kwd id="add16684-kwd-0004">Suboxone</kwd><kwd id="add16684-kwd-0005">substance use</kwd><kwd id="add16684-kwd-0006">treatment retention</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Centers for Disease Control and Prevention
</institution><institution-id institution-id-type="doi">10.13039/100000030</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="12"/><word-count count="7400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:13.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="add16684-cit-9001"><string-name name-style="western"><surname>Young</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hasan</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Alinezhad</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Noor&#8208;E&#8208;Alam</surname><given-names>M</given-names></string-name>. <article-title>Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient&#8208; and prescriber&#8208;level characteristics in Massachusetts, USA</article-title>. <source>Addiction</source>. <year>2025</year>;<volume>120</volume>(<issue>1</issue>):<fpage>152</fpage>&#8211;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1111/add.16684</pub-id><pub-id pub-id-type="pmcid">PMC11638526</pub-id><pub-id pub-id-type="pmid">39397274</pub-id></mixed-citation>
</p><fn-group id="add16684-ntgp-0001"><fn id="add16684-note-0001"><p>
<bold>Funding information</bold> Financial support for this work was provided by the Centers for Disease Control and Prevention through the Overdose Data to Action (OD2A) program.</p></fn></fn-group></notes></front><body id="add16684-body-0001"><sec id="add16684-sec-0008"><title>INTRODUCTION</title><p>During the last two decades, millions of individuals in the United States (US) have developed opioid use disorder (OUD), a condition characterized by a problematic pattern of opioid use that causes significant impairment or distress [<xref rid="add16684-bib-0001" ref-type="bibr">1</xref>]. This epidemic of addiction has had devastating consequences worldwide, as over 60 million people struggle with the addictive effects of opioids globally and more than 100&#8201;000 people die every year of an opioid overdose. In the United States alone there were 80&#8201;000 fatal overdoses involving opioids in 2022 [<xref rid="add16684-bib-0002" ref-type="bibr">2</xref>, <xref rid="add16684-bib-0003" ref-type="bibr">3</xref>, <xref rid="add16684-bib-0004" ref-type="bibr">4</xref>, <xref rid="add16684-bib-0005" ref-type="bibr">5</xref>, <xref rid="add16684-bib-0006" ref-type="bibr">6</xref>, <xref rid="add16684-bib-0007" ref-type="bibr">7</xref>, <xref rid="add16684-bib-0008" ref-type="bibr">8</xref>, <xref rid="add16684-bib-0009" ref-type="bibr">9</xref>, <xref rid="add16684-bib-0010" ref-type="bibr">10</xref>].</p><p>Fortunately, OUD is a treatable condition. Buprenorphine/naloxone is one of three medications that the US Food and Drug Administration (FDA) has approved for the treatment of OUD. The medication has become widely used in the United States [<xref rid="add16684-bib-0011" ref-type="bibr">11</xref>] as well in other countries such as Austria and France where opioid addiction has also been prevalent [<xref rid="add16684-bib-0012" ref-type="bibr">12</xref>, <xref rid="add16684-bib-0013" ref-type="bibr">13</xref>]. In the United States, clinicians can prescribe buprenorphine/naloxone in office settings to treat OUD. Research has shown that successful treatment with this medication is associated with reduced morbidity and mortality [<xref rid="add16684-bib-0014" ref-type="bibr">14</xref>, <xref rid="add16684-bib-0015" ref-type="bibr">15</xref>, <xref rid="add16684-bib-0016" ref-type="bibr">16</xref>, <xref rid="add16684-bib-0017" ref-type="bibr">17</xref>]. However, although buprenorphine offers much promise for patients with OUD, studies indicate that many patients discontinue treatment well under 12&#8201;months; a timeframe that is considered by many experts to be too short to achieve long&#8208;term abstinence [<xref rid="add16684-bib-0018" ref-type="bibr">18</xref>, <xref rid="add16684-bib-0019" ref-type="bibr">19</xref>, <xref rid="add16684-bib-0020" ref-type="bibr">20</xref>]. Even during the time that patients are in treatment, medication adherence is often inconsistent [<xref rid="add16684-bib-0021" ref-type="bibr">21</xref>, <xref rid="add16684-bib-0022" ref-type="bibr">22</xref>, <xref rid="add16684-bib-0023" ref-type="bibr">23</xref>].</p><p>A number of studies have examined the influence of patient&#8208;level characteristics on treatment outcomes for those receiving buprenorphine for OUD. Such characteristics as age, sex and health status have been shown to be influential [<xref rid="add16684-bib-0018" ref-type="bibr">18</xref>, <xref rid="add16684-bib-0024" ref-type="bibr">24</xref>]. Much less attention has been given to the possible influence of prescriber&#8208;level characteristics on patient outcomes. In this paper, we report results from an investigation that leveraged a unique database to assess the influence of patient&#8208; and prescriber&#8208;level characteristics on several types of patient outcomes. We assessed outcomes for a follow&#8208;up period of 12&#8201;months from initiation of buprenorphine treatment, because this is a critically important timeframe for patients when they are highly vulnerable to treatment discontinuation and adverse outcomes.</p></sec><sec sec-type="methods" id="add16684-sec-0009"><title>METHODS</title><sec id="add16684-sec-0010"><title>Data</title><p>We used the Public Health Data Warehouse (PHD) from the Massachusetts Department of Public Health (MDPH). The PHD was authorized under state legislation (M.G.L. c. 111, &#167;237) and comprises numerous datasets that have been linked together through unique identifiers for individuals who have had encounters with healthcare providers within the state and have insurance coverage through a commercial plan or Medicaid (i.e. MassHealth). The datasets include patient&#8208;level medical and pharmacy claims that have been submitted to the state's All&#8208;Payer Claims Database (APCD), prescription monitoring program records, fatal and non&#8208;fatal opioid overdose records and patient&#8208;level demographic information. There also exists unique National Provider Identifiers (NPIs) for the prescribers of record for medications, including buprenorphine.</p><p>We had access to claims and related data for years 2014 through 2020, which were all the years of data available at the time we conducted the study. Both the patient and prescriber unique identifiers provided excellent linkages across the data sets with no gaps or other limitations. However, the PHD does not contain complete information for all commercially insured patients in Massachusetts. This is because self&#8208;insured health plans have not been required to submit claims to state APCDs since a Supreme Court Decision in 2016 (Gobeille v. Liberty Mutual Insurance Company, 577&#8201;US [2016]) determined that self&#8208;insured plans were exempt under the Employee Retirement Income Security Act of 1974. Based on our analysis of claims in the APCD before and after 2015, this reduces the total number of complete patient records in the PHD by ~20% to 30%. For such individuals who received a prescription for buprenorphine, their refill history is documented in the state's prescription monitoring program (which is included in the PHD), but no other information is available regarding medical history including chronic health conditions. We also used a dataset from the Substance Abuse and Mental Health Services Administration (SAMHSA) that provided information pertaining to prescribers' buprenorphine Data Waiver status. This study was approved by The Northeastern University Institutional Review Board (IRB 15&#8211;11&#8208;18). A pre&#8208;registration filing was not submitted for the study. The datasets from the PHD that we analyzed for the study are not publicly available because of a data use agreement between the authors and MDPH. Information about the PHD and the application process to request the data can be obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mass.gov/public-health-data-warehouse-phd" ext-link-type="uri">https://www.mass.gov/public-health-data-warehouse-phd</ext-link> (<email>dph.phd@mass.gov</email>).</p></sec><sec id="add16684-sec-0011"><title>Study sample</title><p>We constructed a sample comprised of patients who initiated buprenorphine treatment during the study timeframe and the prescribers who were primarily responsible for managing the patients' therapy from the time of treatment initiation through the 12&#8208;month follow&#8208;up period. We included individuals who were at least 18&#8201;years of age, had a prescription for buprenorphine sometime between 2015 and 2019, had a documented diagnosis for OUD, were continuously insured for the entire study period through a commercial plan or Medicaid and for whom insurance claims were available within the PHD.</p><p>We determined that buprenorphine was prescribed for OUD by checking the diagnostic codes on patient claims. Only individuals with documented buprenorphine prescriptions and OUD diagnostic codes were included in the sample. We also confined the study sample to individuals who were receiving buprenorphine that was formulated for OUD (vs. formulations for pain only) and were regularly self&#8208;administering the medication (i.e. there were few claims during the study period for the injectable or extended release forms of the medication). We excluded individuals who were not Massachusetts residents. We also excluded individuals who had less than two buprenorphine prescriptions during the study period, because some patients receive a prescription following an opioid&#8208;related event (e.g. overdose), but have not at this point elected to participate in buprenorphine treatment. This approach is in line with previous research [<xref rid="add16684-bib-0022" ref-type="bibr">22</xref>, <xref rid="add16684-bib-0025" ref-type="bibr">25</xref>, <xref rid="add16684-bib-0026" ref-type="bibr">26</xref>]. In addition, we excluded patients who had one or more buprenorphine prescriptions within 12&#8201;months before the focal prescription because our intention was to focus on patients who were na&#239;ve to buprenorphine or had not elected such treatment for an extended period of time. Finally, we excluded from the sample individuals who died for reasons other than an opioid&#8208;related overdose as such deaths were likely unrelated to buprenorphine treatment (Figure&#160;<xref rid="add16684-fig-0001" ref-type="fig">1</xref>). Each patient was included in the study sample only once based on when they first met the study criteria.</p><fig position="float" fig-type="FIGURE" id="add16684-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flow diagram for sample selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ADD-120-152-g001.jpg"/></fig><p>Because some patients had more than one prescriber during the follow&#8208;up period, we assigned to each patient a primary prescriber, designated as the prescriber of record for the plurality of buprenorphine pharmacy claims during that patient's follow&#8208;up period. We used pharmacy claims to identify the index prescription in each year of the study.</p></sec><sec id="add16684-sec-0012"><title>Outcome measures</title><p>We examined three types of outcomes following treatment initiation. As noted, we assessed outcomes that occurred up to 12&#8201;months from the time of the initial prescription for buprenorphine. One outcome was a measure of continuity of care for the medication treatment of OUD that has been endorsed by the National Quality Forum (NQF), a US&#8208;based organization that has a key role in reviewing and endorsing measures pertaining to quality of care [<xref rid="add16684-bib-0027" ref-type="bibr">27</xref>]. This measure defines minimally acceptable medication continuity as patients having at least 180&#8201;days of continuous pharmacotherapy with a medication prescribed for OUD without medication gaps totaling more than 7&#160;days. The measure is intended to capture medication adherence during the early phase of treatment when the role of the prescriber in managing such adherence may be most meaningful [<xref rid="add16684-bib-0028" ref-type="bibr">28</xref>]. We adapted this measure to assess poor medication continuity during the early phase of treatment, defined as a patient having medication gaps totaling more than 7&#160;days within the initial 180&#8201;days of buprenorphine treatment (i.e. more than 7 days where the patient did not appear to have the medication available based on prescription refill data). Another outcome was treatment discontinuation, which, following previous research, we defined as a medication gap of 2 consecutive months (i.e. 60&#8201;days) within the 12&#8208;month follow&#8208;up period [<xref rid="add16684-bib-0018" ref-type="bibr">18</xref>, <xref rid="add16684-bib-0021" ref-type="bibr">21</xref>, <xref rid="add16684-bib-0029" ref-type="bibr">29</xref>, <xref rid="add16684-bib-0030" ref-type="bibr">30</xref>]. Patients meeting this definition of discontinuation within 180&#8201;days from the time of treatment initiation would also meet the definition of poor medication continuity. The third outcome was opioid overdose, both fatal and non&#8208;fatal, at any point during the 12&#8208;month follow&#8208;up period. We determined that a patient overdosed by referring to a data set within the PHD that is informed with reports submitted by hospitals and the office of the state medical examiner. We excluded from the computations of medication continuity and discontinuation patients who experienced a fatal overdose.</p></sec><sec id="add16684-sec-0013"><title>Patient characteristics</title><p>Patient&#8208;level characteristics included age, sex, insurance coverage, pre&#8208;treatment health status and history of substance use disorder. For age, we assigned individuals to one of several categories&#8212;18 to 35, 36 to 45 and &gt;45&#8201;years. Insurance coverage included commercial, Medicaid and Medicare. Medicare is a federally administered insurance program for individuals age 65&#8201;years and older and those with certain disabilities, whereas Medicaid is a joint federal and state insurance program for individuals whose income and financial resources fall below defined thresholds. Commercial insurance is provided through private health plans and a high percentage of individuals in the United States secure such commercial coverage from their employer [<xref rid="add16684-bib-0031" ref-type="bibr">31</xref>]. We did not have claims for patients enrolled in original Medicare. Our sample of Medicare patients was confined to those who were enrolled in a Medicare Advantage plan (a private plan alternative to original Medicare for which commercial claims are available). For pre&#8208;treatment health status, we relied on information from a patient's medical claims extending back to 12&#8201;months from the time of treatment initiation. We assigned patients to one of three categories based on their Charlson Comorbidity Index score (i.e. 0, 1&#8211;2, &gt;2), which is a widely used tool for categorizing comorbidities in regard to their impact on an individual's likelihood of survival [<xref rid="add16684-bib-0032" ref-type="bibr">32</xref>]. We also accounted for whether the patient had a history of mental health conditions, specifically anxiety (dichotomous variable with indicator for yes; zero otherwise) or depression (dichotomous variable with indicator for yes; zero otherwise). In addition, we included whether the patient had a history of substance use disorder outside of opioids (dichotomous variable with indicator for yes; zero otherwise).</p></sec><sec id="add16684-sec-0014"><title>Prescriber characteristics</title><p>For prescriber&#8208;level characteristics, we included fixed and time&#8208;varying characteristics, specifically clinical training, panel size and a proxy for prescribing experience with buprenorphine. For clinical training, a fixed characteristic, we focused on the three most common types of prescribers in our dataset: primary care physicians (PCPs) (this includes internal and family medicine), psychiatrists and nurse practitioners. We assigned other types of prescribers to a general category (e.g. emergency room physicians, anesthesiologists, surgeons and physical medicine and rehabilitation clinicians). As a time&#8208;varying characteristic, we accounted for the size of a prescriber's panel of insured patients undergoing buprenorphine treatment for OUD. Panel size was based on a prescriber's total number of patients for a given calendar year during the study timeframe. Although this measure does not align precisely with patient follow&#8208;up periods, it is likely to match up fairly closely to the prescriber's panel size for patients who initiated treatment at some point during that year. For each year in the study timeframe, we then assigned each prescriber to one of three categories that matched prescriber thresholds used by the federal government until 2023 under the buprenorphine waiver regulations [<xref rid="add16684-bib-0033" ref-type="bibr">33</xref>]. These categories are the following: 30 or fewer, 31 to 100 and more than 100 patients. For prescribing experience, another time&#8208;varying characteristic, we used the previously noted SAMHSA database to determine when a prescriber was first authorized to prescribe buprenorphine for treating OUD. We used this as a proxy for the actual prescribing experience because we lacked sufficient data to determine when all prescribers first began to actually prescribe buprenorphine. For each calendar year in the study timeframe, we assigned prescribers to one of several categories based on the number of years that had elapsed since they were first authorized to prescribe buprenorphine (&lt;1&#160;year, 1&#8211;3&#160;years, and &gt;3&#160;years).</p></sec><sec id="add16684-sec-0015"><title>Statistical analysis</title><p>We computed descriptive statistics for patients and prescribers included in the study sample. For prescribers, we computed descriptive statistics on panel size and experience based on prescriber&#8208;level annual averages during the study period as the values of these variables change from year&#8208;to&#8208;year. We report prescriber&#8208;level outcomes based on all the patients for whom a prescriber was designated as the primary prescriber during the study timeframe. Specifically, we computed the mean prescriber&#8208;level rates for each outcome for all unique patients attributed to a prescriber during the study timeframe. We also computed the mean prescriber&#8208;level rates for each outcome for only those prescribers who were the designated prescriber for at least 20 unique patients during the study timeframe.</p><p>For the analysis that included both patient&#8208; and prescriber&#8208;level characteristics, we used a multi&#8208;level modeling approach that allowed us to assess patient outcomes at the level of the patient and prescriber. As such, a third level was included in the model to account for the time&#8208;varying nature of prescriber panel size and prescribing experience. Therefore, prescribers were nested within years and patients within prescribers. As each outcome was a binary variable, we estimated models with logistic regression and computed odds ratios with 95% CIs, which were the thresholds for identifying relationships as statistically significant. We also computed intraclass correlation (ICC) values at the prescriber level to assess the amount of variation among patient outcomes accounted for by prescribers. We undertook several sensitivity analyses. In one such analysis, we re&#8208;estimated the model to include only those patients whose designated prescriber had 20 or more patients during the study timeframe. We undertook this analysis to reduce the effect of small sample size on prescriber&#8208;level outcomes. In another sensitivity analysis, we estimated a model for fatal overdoses specifically to compare the results with the model that included all opioid overdoses. As a third analysis, we re&#8208;estimated the models after excluding patients who transitioned during the follow&#8208;up period from buprenorphine treatment to naltrexone (one of two other FDA approved medications for the treatment of OUD) that we were able to track through prescription claims. The third medication is methadone, but information regarding patients undergoing methadone treatment is not reliably reported to the PHD. All study analyses were conducted using Statistical Analysis System (SAS) software (version 9.4_M7).</p></sec></sec><sec sec-type="results" id="add16684-sec-0016"><title>RESULTS</title><p>Using the PHD, we identified 37&#8201;955 patients who initiated a new buprenorphine prescription between 2015 and 2019 and met the study's inclusion criteria. Table&#160;<xref rid="add16684-tbl-0001" ref-type="table">1</xref> presents descriptive statistics for these patients. A total of 53.7% of the patients included in the sample received treatment from a prescriber who, in the year that such treatment was initiated, had a panel size greater than 100 and 21.5% of the patients were treated by a prescriber who had less than 1&#160;year of prescribing experience for buprenorphine. The overall rates for poor medication continuity, discontinuation and opioid overdose during the follow&#8208;up period were 59.7% (95% CI = 59.2&#8211;60.2), 57.4% (95% CI = 56.9&#8211;57.9) and 10.3% (95% CI = 10.0&#8211;10.6), respectively. Approximately 1% of the patients experienced a fatal overdose during the follow&#8208;up period, which is higher than the statewide rate for Massachusetts as of 2022 (i.e. 0.033) [<xref rid="add16684-bib-0034" ref-type="bibr">34</xref>].</p><table-wrap position="float" id="add16684-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Descriptive statistics for patients who initiated buprenorphine treatment between 2016 and 2019.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Patient characteristics</th><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">No. of patients</th><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">%</th><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">NQF poor medication continuity %</th><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Discontinuation %</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Opioid overdose</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">All %</th><th align="left" valign="bottom" rowspan="1" colspan="1">Fatal %</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">All</td><td align="left" valign="top" rowspan="1" colspan="1">37&#8201;955</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">59.7</td><td align="left" valign="top" rowspan="1" colspan="1">57.4</td><td align="left" valign="top" rowspan="1" colspan="1">10.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">24&#8201;508</td><td align="left" valign="top" rowspan="1" colspan="1">64.6</td><td align="left" valign="top" rowspan="1" colspan="1">61.0</td><td align="left" valign="top" rowspan="1" colspan="1">59.4</td><td align="left" valign="top" rowspan="1" colspan="1">11.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;447</td><td align="left" valign="top" rowspan="1" colspan="1">35.4</td><td align="left" valign="top" rowspan="1" colspan="1">57.5</td><td align="left" valign="top" rowspan="1" colspan="1">53.9</td><td align="left" valign="top" rowspan="1" colspan="1">8.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, y</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">18&#8211;34</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;958</td><td align="left" valign="top" rowspan="1" colspan="1">52.6</td><td align="left" valign="top" rowspan="1" colspan="1">65.2</td><td align="left" valign="top" rowspan="1" colspan="1">62.7</td><td align="left" valign="top" rowspan="1" colspan="1">12.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">35&#8211;45</td><td align="left" valign="top" rowspan="1" colspan="1">9255</td><td align="left" valign="top" rowspan="1" colspan="1">24.4</td><td align="left" valign="top" rowspan="1" colspan="1">57.1</td><td align="left" valign="top" rowspan="1" colspan="1">54.3</td><td align="left" valign="top" rowspan="1" colspan="1">9.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt;45</td><td align="left" valign="top" rowspan="1" colspan="1">8742</td><td align="left" valign="top" rowspan="1" colspan="1">23.0</td><td align="left" valign="top" rowspan="1" colspan="1">50.0</td><td align="left" valign="top" rowspan="1" colspan="1">48.7</td><td align="left" valign="top" rowspan="1" colspan="1">6.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insurance</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Commercial</td><td align="left" valign="top" rowspan="1" colspan="1">7083</td><td align="left" valign="top" rowspan="1" colspan="1">18.7</td><td align="left" valign="top" rowspan="1" colspan="1">53.4</td><td align="left" valign="top" rowspan="1" colspan="1">52.5</td><td align="left" valign="top" rowspan="1" colspan="1">4.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Medicaid</td><td align="left" valign="top" rowspan="1" colspan="1">27&#8201;373</td><td align="left" valign="top" rowspan="1" colspan="1">72.1</td><td align="left" valign="top" rowspan="1" colspan="1">62.7</td><td align="left" valign="top" rowspan="1" colspan="1">59.4</td><td align="left" valign="top" rowspan="1" colspan="1">12.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Medicare</td><td align="left" valign="top" rowspan="1" colspan="1">1211</td><td align="left" valign="top" rowspan="1" colspan="1">3.2</td><td align="left" valign="top" rowspan="1" colspan="1">44.8</td><td align="left" valign="top" rowspan="1" colspan="1">46.9</td><td align="left" valign="top" rowspan="1" colspan="1">6.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other<xref rid="add16684-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2288</td><td align="left" valign="top" rowspan="1" colspan="1">6.0</td><td align="left" valign="top" rowspan="1" colspan="1">51.9</td><td align="left" valign="top" rowspan="1" colspan="1">54.6</td><td align="left" valign="top" rowspan="1" colspan="1">8.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White non&#8208;Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">31&#8201;194</td><td align="left" valign="top" rowspan="1" colspan="1">82.2</td><td align="left" valign="top" rowspan="1" colspan="1">59.0</td><td align="left" valign="top" rowspan="1" colspan="1">56.1</td><td align="left" valign="top" rowspan="1" colspan="1">10.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black non&#8208;Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">1797</td><td align="left" valign="top" rowspan="1" colspan="1">4.7</td><td align="left" valign="top" rowspan="1" colspan="1">67.4</td><td align="left" valign="top" rowspan="1" colspan="1">63.7</td><td align="left" valign="top" rowspan="1" colspan="1">11.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">4262</td><td align="left" valign="top" rowspan="1" colspan="1">11.3</td><td align="left" valign="top" rowspan="1" colspan="1">62.7</td><td align="left" valign="top" rowspan="1" colspan="1">64.5</td><td align="left" valign="top" rowspan="1" colspan="1">11.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">702</td><td align="left" valign="top" rowspan="1" colspan="1">1.8</td><td align="left" valign="top" rowspan="1" colspan="1">55.3</td><td align="left" valign="top" rowspan="1" colspan="1">55.7</td><td align="left" valign="top" rowspan="1" colspan="1">4.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Charlson Comorbidity Index</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">24&#8201;487</td><td align="left" valign="top" rowspan="1" colspan="1">64.5</td><td align="left" valign="top" rowspan="1" colspan="1">59.6</td><td align="left" valign="top" rowspan="1" colspan="1">57.5</td><td align="left" valign="top" rowspan="1" colspan="1">8.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1&#8211;2</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;913</td><td align="left" valign="top" rowspan="1" colspan="1">28.8</td><td align="left" valign="top" rowspan="1" colspan="1">60.6</td><td align="left" valign="top" rowspan="1" colspan="1">57.5</td><td align="left" valign="top" rowspan="1" colspan="1">13.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt;2</td><td align="left" valign="top" rowspan="1" colspan="1">2555</td><td align="left" valign="top" rowspan="1" colspan="1">6.7</td><td align="left" valign="top" rowspan="1" colspan="1">57.2</td><td align="left" valign="top" rowspan="1" colspan="1">56.3</td><td align="left" valign="top" rowspan="1" colspan="1">12.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mental health</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">24&#8201;681</td><td align="left" valign="top" rowspan="1" colspan="1">65.0</td><td align="left" valign="top" rowspan="1" colspan="1">60.8</td><td align="left" valign="top" rowspan="1" colspan="1">57.9</td><td align="left" valign="top" rowspan="1" colspan="1">11.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;274</td><td align="left" valign="top" rowspan="1" colspan="1">35.0</td><td align="left" valign="top" rowspan="1" colspan="1">57.6</td><td align="left" valign="top" rowspan="1" colspan="1">56.5</td><td align="left" valign="top" rowspan="1" colspan="1">7.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other substance use disorder<xref rid="add16684-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;671</td><td align="left" valign="top" rowspan="1" colspan="1">36.0</td><td align="left" valign="top" rowspan="1" colspan="1">68.3</td><td align="left" valign="top" rowspan="1" colspan="1">65.5</td><td align="left" valign="top" rowspan="1" colspan="1">16.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">24&#8201;284</td><td align="left" valign="top" rowspan="1" colspan="1">64.0</td><td align="left" valign="top" rowspan="1" colspan="1">54.9</td><td align="left" valign="top" rowspan="1" colspan="1">52.9</td><td align="left" valign="top" rowspan="1" colspan="1">6.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prescriber's clinical training</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Psychiatry</td><td align="left" valign="top" rowspan="1" colspan="1">5569</td><td align="left" valign="top" rowspan="1" colspan="1">14.7</td><td align="left" valign="top" rowspan="1" colspan="1">57.5</td><td align="left" valign="top" rowspan="1" colspan="1">55.1</td><td align="left" valign="top" rowspan="1" colspan="1">10.0</td><td align="left" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Primary care</td><td align="left" valign="top" rowspan="1" colspan="1">15&#8201;794</td><td align="left" valign="top" rowspan="1" colspan="1">41.6</td><td align="left" valign="top" rowspan="1" colspan="1">62.3</td><td align="left" valign="top" rowspan="1" colspan="1">57.8</td><td align="left" valign="top" rowspan="1" colspan="1">10.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nurse practitioner</td><td align="left" valign="top" rowspan="1" colspan="1">1410</td><td align="left" valign="top" rowspan="1" colspan="1">3.7</td><td align="left" valign="top" rowspan="1" colspan="1">63.6</td><td align="left" valign="top" rowspan="1" colspan="1">56.8</td><td align="left" valign="top" rowspan="1" colspan="1">10.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">15&#8201;182</td><td align="left" valign="top" rowspan="1" colspan="1">40.0</td><td align="left" valign="top" rowspan="1" colspan="1">57.5</td><td align="left" valign="top" rowspan="1" colspan="1">57.9</td><td align="left" valign="top" rowspan="1" colspan="1">9.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prescriber's patient volume<xref rid="add16684-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0&#8211;30</td><td align="left" valign="top" rowspan="1" colspan="1">4816</td><td align="left" valign="top" rowspan="1" colspan="1">12.7</td><td align="left" valign="top" rowspan="1" colspan="1">53.2</td><td align="left" valign="top" rowspan="1" colspan="1">55.9</td><td align="left" valign="top" rowspan="1" colspan="1">9.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">31&#8211;100</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;774</td><td align="left" valign="top" rowspan="1" colspan="1">33.7</td><td align="left" valign="top" rowspan="1" colspan="1">55.1</td><td align="left" valign="top" rowspan="1" colspan="1">54.3</td><td align="left" valign="top" rowspan="1" colspan="1">9.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt;100</td><td align="left" valign="top" rowspan="1" colspan="1">20&#8201;365</td><td align="left" valign="top" rowspan="1" colspan="1">53.6</td><td align="left" valign="top" rowspan="1" colspan="1">64.2</td><td align="left" valign="top" rowspan="1" colspan="1">59.7</td><td align="left" valign="top" rowspan="1" colspan="1">10.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prescriber's years of experience</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&lt;1</td><td align="left" valign="top" rowspan="1" colspan="1">8165</td><td align="left" valign="top" rowspan="1" colspan="1">21.5</td><td align="left" valign="top" rowspan="1" colspan="1">57.7</td><td align="left" valign="top" rowspan="1" colspan="1">59.6</td><td align="left" valign="top" rowspan="1" colspan="1">10.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1&#8211;3</td><td align="left" valign="top" rowspan="1" colspan="1">22&#8201;879</td><td align="left" valign="top" rowspan="1" colspan="1">60.3</td><td align="left" valign="top" rowspan="1" colspan="1">61.1</td><td align="left" valign="top" rowspan="1" colspan="1">57.2</td><td align="left" valign="top" rowspan="1" colspan="1">10.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt;3</td><td align="left" valign="top" rowspan="1" colspan="1">6911</td><td align="left" valign="top" rowspan="1" colspan="1">18.2</td><td align="left" valign="top" rowspan="1" colspan="1">57.3</td><td align="left" valign="top" rowspan="1" colspan="1">55.5</td><td align="left" valign="top" rowspan="1" colspan="1">9.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.1</td></tr></tbody></table><table-wrap-foot id="add16684-ntgp-0002"><fn id="add16684-note-0002"><p>Abbreviation: NQF, National Quality Forum.</p></fn><fn id="add16684-note-0003"><label>
<sup>a</sup>
</label><p>Includes patients covered by certain government insurance programs other than Medicare and Medicaid.</p></fn><fn id="add16684-note-0004"><label>
<sup>b</sup>
</label><p>The substances for this variable included alcohol, cocaine, amphetamines, benzodiazepines, barbiturates, tranquilizers and methamphetamines.</p></fn><fn id="add16684-note-0005"><label>
<sup>c</sup>
</label><p>These are mean rates for prescribers in the sample.</p></fn></table-wrap-foot></table-wrap><p>Table&#160;<xref rid="add16684-tbl-0002" ref-type="table">2</xref> presents descriptive statistics at the prescriber level. The study sample comprised a total of 2146 unique prescribers. Of these prescribers, 58.5% were either a PCP, psychiatrist or nurse practitioner. For each patient, the designated primary prescriber was, on average, responsible for more than 75% of the patient's total pharmacy claims for buprenorphine during the 12&#8208;month follow&#8208;up period. The mean prescriber&#8208;level panel size during the study timeframe was 40.0 (SD&#8201;=&#8201;56.6) and the mean buprenorphine prescribing experience was 1.9&#160;years (SD&#8201;=&#8201;2.6). During the study timeframe, 26.3% of the prescribers had a change in their panel size such that they moved from one of the size categories used for the analysis to another category (not reported in tables). The mean prescriber&#8208;level outcomes for poor continuity and discontinuation were comparable between prescribers with relatively larger (&#8805;20) and smaller (&lt;20) patient panels (poor continuity, 57.6% vs. 57.7%; overdose, 10.2% vs. 10.0%). Prescribers with a larger panel size had statistically significant higher discontinuation compared with prescribers with a smaller panel size (61.6 vs. 55.9, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). Moreover, the SDs indicate considerable variation at the prescriber level for these outcomes, particularly for the prescribers with relatively smaller panels.</p><table-wrap position="float" id="add16684-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Descriptive statistics for prescribers (full sample comprises 2146 prescribers) who prescribed buprenorphine to patients included in the study sample.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mean/%</th><th align="left" valign="bottom" rowspan="1" colspan="1">SD</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Clinical training</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Psychiatry (%)</td><td align="left" valign="top" rowspan="1" colspan="1">337</td><td align="left" valign="top" rowspan="1" colspan="1">15.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Primary care (%)</td><td align="left" valign="top" rowspan="1" colspan="1">700</td><td align="left" valign="top" rowspan="1" colspan="1">32.6</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nurse practitioner (%)</td><td align="left" valign="top" rowspan="1" colspan="1">219</td><td align="left" valign="top" rowspan="1" colspan="1">10.2</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other (%)</td><td align="left" valign="top" rowspan="1" colspan="1">890</td><td align="left" valign="top" rowspan="1" colspan="1">41.5</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Experience (y)</td><td align="left" valign="top" rowspan="1" colspan="1">2146</td><td align="left" valign="top" rowspan="1" colspan="1">1.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.6</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Panel size</td><td align="left" valign="top" rowspan="1" colspan="1">2146</td><td align="left" valign="top" rowspan="1" colspan="1">40.0</td><td align="left" valign="top" rowspan="1" colspan="1">56.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">All prescriber outcomes</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NQF poor continuity</td><td align="left" valign="top" rowspan="1" colspan="1">2146</td><td align="left" valign="top" rowspan="1" colspan="1">57.6</td><td align="left" valign="top" rowspan="1" colspan="1">34.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">2146</td><td align="left" valign="top" rowspan="1" colspan="1">59.0</td><td align="left" valign="top" rowspan="1" colspan="1">33.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Overdose</td><td align="left" valign="top" rowspan="1" colspan="1">2146</td><td align="left" valign="top" rowspan="1" colspan="1">10.1</td><td align="left" valign="top" rowspan="1" colspan="1">19.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prescriber with &#8805;20 patients' outcome</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NQF poor continuity</td><td align="left" valign="top" rowspan="1" colspan="1">997</td><td align="left" valign="top" rowspan="1" colspan="1">57.6</td><td align="left" valign="top" rowspan="1" colspan="1">22.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">997</td><td align="left" valign="top" rowspan="1" colspan="1">55.9</td><td align="left" valign="top" rowspan="1" colspan="1">19.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Opioid overdose</td><td align="left" valign="top" rowspan="1" colspan="1">997</td><td align="left" valign="top" rowspan="1" colspan="1">10.2</td><td align="left" valign="top" rowspan="1" colspan="1">11.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prescriber with &lt;20 patients' outcome</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NQF poor continuity</td><td align="left" valign="top" rowspan="1" colspan="1">1149</td><td align="left" valign="top" rowspan="1" colspan="1">57.7</td><td align="left" valign="top" rowspan="1" colspan="1">42.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">1149</td><td align="left" valign="top" rowspan="1" colspan="1">61.6</td><td align="left" valign="top" rowspan="1" colspan="1">41.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Opioid overdose</td><td align="left" valign="top" rowspan="1" colspan="1">1149</td><td align="left" valign="top" rowspan="1" colspan="1">10.0</td><td align="left" valign="top" rowspan="1" colspan="1">25.1</td></tr></tbody></table><table-wrap-foot id="add16684-ntgp-0003"><fn id="add16684-note-0006"><p>Abbreviation: NQF, National Quality Forum.</p></fn></table-wrap-foot></table-wrap><p>Table&#160;<xref rid="add16684-tbl-0003" ref-type="table">3</xref> presents adjusted odds ratios from the multi&#8208;level models (unadjusted odds ratios are presented in Appendix&#160;<xref rid="add16684-supitem-0001" ref-type="supplementary-material">S1</xref>). Both patient&#8208; and prescriber&#8208;level characteristics were associated with one or more outcomes. At the patient level, after adjustment for covariates, male patients had higher odds of experiencing adverse outcomes for each of the three models (poor continuity: 1.17, 95% CI = 1.11&#8211;1.22; discontinuation: 1.25, 95% CI = 1.20&#8211;1.31; overdose: 1.53, 95% CI = 1.42&#8211;1.65), as did younger patients particularly those under the age of 35 (poor continuity: 1.78, 95% CI = 1.68&#8211;1.89; discontinuation: 1.73, 95% CI = 1.63&#8211;1.84; overdose: 1.93, 95% CI = 1.74&#8211;2.14). Patients with Medicaid coverage had higher odds of experiencing the adverse outcomes in all three models relative to those with commercial insurance (poor continuity: 1.18, 95% CI = 1.11&#8211;1.26; discontinuation: 1.09, 95% CI = 1.03&#8211;1.16; overdose: 1.98, 95% CI = 1.75&#8211;2.23). In particular, those with Medicaid coverage had almost double the odds of opioid overdose. Those with Medicare coverage had, relative to commercially insured patients, lower odds of poor medication continuity, but higher odds of opioid overdose (poor continuity: 0.73, 95% CI = 0.64&#8211;0.84; overdose: 1.49, 95% CI = 1.15&#8211;1.92). With respect to race/ethnicity, Black, non&#8208;Hispanic patients had higher odds of poor medication continuity and treatment discontinuation relative to White, non&#8208;Hispanic patients (poor continuity: 1.50, 95% CI = 1.34&#8211;1.68; discontinuation: 1.44, 95% CI = 1.30&#8211;1.60) as did Hispanic patients (poor continuity: 1.21, 95% CI = 1.12&#8211;1.31; discontinuation: 1.38, 95% CI = 1.28&#8211;1.48). For these patients, the odds of treatment discontinuation were more than 30% greater than for White, non&#8208;Hispanic patients. With respect to pre&#8208;treatment health status, patients with more chronic health conditions (i.e. &gt;2) had higher odds of experiencing all adverse outcomes in all three models (poor continuity: 1.15, 95% CI = 1.05&#8211;1.27; discontinuation: 1.15, 95% CI = 1.05&#8211;1.26; overdose: 1.83, 95% CI = 1.83, 1.60&#8211;2.10). This was also true of patients with a history of mental health conditions (poor continuity: 1.11, 95% CI = 1.06&#8211;1.17; discontinuation: 1.05, 95% CI = 1.01&#8211;1.10; overdose: 1.47, 95% CI = 1.36&#8211;1.60) and a history of substance use disorder other than for opioids (poor continuity: 1.54, 95% CI = 1.46&#8211;1.62; discontinuation: 1.54, 95% CI = 1.47&#8211;1.62; overdose: 1.93, 95% CI = 1.80&#8211;2.07). We have summarized the results presented in Table&#160;<xref rid="add16684-tbl-0003" ref-type="table">3</xref> in a forest plot (Figure&#160;<xref rid="add16684-fig-0002" ref-type="fig">2</xref>).</p><table-wrap position="float" id="add16684-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Results from hierarchical models.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Patient level</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">NQF poor continuity</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Discontinuation</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Opioid overdose</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">OR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">OR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">OR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">1.17</td><td align="left" valign="top" rowspan="1" colspan="1">(1.11&#8211;1.22)</td><td align="left" valign="top" rowspan="1" colspan="1">1.25</td><td align="left" valign="top" rowspan="1" colspan="1">(1.20&#8211;1.31)</td><td align="left" valign="top" rowspan="1" colspan="1">1.53</td><td align="left" valign="top" rowspan="1" colspan="1">(1.42&#8211;1.65)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, y</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">18&#8211;34</td><td align="left" valign="top" rowspan="1" colspan="1">1.78</td><td align="left" valign="top" rowspan="1" colspan="1">(1.68&#8211;1.89)</td><td align="left" valign="top" rowspan="1" colspan="1">1.73</td><td align="left" valign="top" rowspan="1" colspan="1">(1.63&#8211;1.84)</td><td align="left" valign="top" rowspan="1" colspan="1">1.93</td><td align="left" valign="top" rowspan="1" colspan="1">(1.74&#8211;2.14)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">35&#8211;45</td><td align="left" valign="top" rowspan="1" colspan="1">1.24</td><td align="left" valign="top" rowspan="1" colspan="1">(1.16&#8211;1.32)</td><td align="left" valign="top" rowspan="1" colspan="1">1.23</td><td align="left" valign="top" rowspan="1" colspan="1">(1.15&#8211;1.31)</td><td align="left" valign="top" rowspan="1" colspan="1">1.43</td><td align="left" valign="top" rowspan="1" colspan="1">(1.28&#8211;1.61)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">&gt;45</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insurance</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Commercial</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Medicaid</td><td align="left" valign="top" rowspan="1" colspan="1">1.18</td><td align="left" valign="top" rowspan="1" colspan="1">(1.11&#8211;1.26)</td><td align="left" valign="top" rowspan="1" colspan="1">1.09</td><td align="left" valign="top" rowspan="1" colspan="1">(1.03&#8211;1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">1.98</td><td align="left" valign="top" rowspan="1" colspan="1">(1.75&#8211;2.23)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Medicare</td><td align="left" valign="top" rowspan="1" colspan="1">0.73</td><td align="left" valign="top" rowspan="1" colspan="1">(0.64&#8211;0.84)</td><td align="left" valign="top" rowspan="1" colspan="1">0.98</td><td align="left" valign="top" rowspan="1" colspan="1">(0.85&#8211;1.11)</td><td align="left" valign="top" rowspan="1" colspan="1">1.49</td><td align="left" valign="top" rowspan="1" colspan="1">(1.15&#8211;1.92)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">(0.83&#8211;1.03)</td><td align="left" valign="top" rowspan="1" colspan="1">1.18</td><td align="left" valign="top" rowspan="1" colspan="1">(1.06&#8211;1.31)</td><td align="left" valign="top" rowspan="1" colspan="1">1.07</td><td align="left" valign="top" rowspan="1" colspan="1">(0.97&#8211;1.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">White non&#8208;Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Black non&#8208;Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">1.50</td><td align="left" valign="top" rowspan="1" colspan="1">(1.34&#8211;1.68)</td><td align="left" valign="top" rowspan="1" colspan="1">1.44</td><td align="left" valign="top" rowspan="1" colspan="1">(1.30&#8211;1.60)</td><td align="left" valign="top" rowspan="1" colspan="1">1.01</td><td align="left" valign="top" rowspan="1" colspan="1">(0.86&#8211;1.18)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">1.21</td><td align="left" valign="top" rowspan="1" colspan="1">(1.12&#8211;1.31)</td><td align="left" valign="top" rowspan="1" colspan="1">1.38</td><td align="left" valign="top" rowspan="1" colspan="1">(1.28&#8211;1.48)</td><td align="left" valign="top" rowspan="1" colspan="1">0.94</td><td align="left" valign="top" rowspan="1" colspan="1">(0.85&#8211;1.05)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">(0.82&#8211;1.14)</td><td align="left" valign="top" rowspan="1" colspan="1">1.06</td><td align="left" valign="top" rowspan="1" colspan="1">(0.91&#8211;1.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.87</td><td align="left" valign="top" rowspan="1" colspan="1">(0.62&#8211;1.12)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mental health condition (yes)</td><td align="left" valign="top" rowspan="1" colspan="1">1.11</td><td align="left" valign="top" rowspan="1" colspan="1">(1.06&#8211;1.17)</td><td align="left" valign="top" rowspan="1" colspan="1">1.05</td><td align="left" valign="top" rowspan="1" colspan="1">(1.00&#8211;1.10)</td><td align="left" valign="top" rowspan="1" colspan="1">1.47</td><td align="left" valign="top" rowspan="1" colspan="1">(1.36&#8211;1.60)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other substance use disorder (yes)</td><td align="left" valign="top" rowspan="1" colspan="1">1.54</td><td align="left" valign="top" rowspan="1" colspan="1">(1.46&#8211;1.62)</td><td align="left" valign="top" rowspan="1" colspan="1">1.54</td><td align="left" valign="top" rowspan="1" colspan="1">(1.47&#8211;1.62)</td><td align="left" valign="top" rowspan="1" colspan="1">1.93</td><td align="left" valign="top" rowspan="1" colspan="1">(1.80&#8211;2.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Charlson Comorbidity Index</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">1&#8211;2</td><td align="left" valign="top" rowspan="1" colspan="1">1.05</td><td align="left" valign="top" rowspan="1" colspan="1">(1.00&#8211;1.11)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1">(0.95&#8211;1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">1.49</td><td align="left" valign="top" rowspan="1" colspan="1">(1.38&#8211;1.61)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">&gt;2</td><td align="left" valign="top" rowspan="1" colspan="1">1.15</td><td align="left" valign="top" rowspan="1" colspan="1">(1.05&#8211;1.27)</td><td align="left" valign="top" rowspan="1" colspan="1">1.15</td><td align="left" valign="top" rowspan="1" colspan="1">(1.05&#8211;1.26)</td><td align="left" valign="top" rowspan="1" colspan="1">1.83</td><td align="left" valign="top" rowspan="1" colspan="1">(1.60&#8211;2.10)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prescriber level</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clinical training</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Psychiatry</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Primary care</td><td align="left" valign="top" rowspan="1" colspan="1">1.12</td><td align="left" valign="top" rowspan="1" colspan="1">(1.02&#8211;1.23)</td><td align="left" valign="top" rowspan="1" colspan="1">1.04</td><td align="left" valign="top" rowspan="1" colspan="1">(1.01&#8211;1.09)</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">(0.89&#8211;1.11)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Nurse practitioner</td><td align="left" valign="top" rowspan="1" colspan="1">1.15</td><td align="left" valign="top" rowspan="1" colspan="1">(0.97&#8211;1.37)</td><td align="left" valign="top" rowspan="1" colspan="1">1.09</td><td align="left" valign="top" rowspan="1" colspan="1">(0.93&#8211;1.26)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">(0.78&#8211;1.19)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Other physician</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">(0.82&#8211;1.02)</td><td align="left" valign="top" rowspan="1" colspan="1">1.09</td><td align="left" valign="top" rowspan="1" colspan="1">(1.01&#8211;1.18)</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">(0.88&#8211;1.10)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient volume</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Low (0&#8211;30)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">(0.88&#8211;1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">1.13</td><td align="left" valign="top" rowspan="1" colspan="1">(1.04&#8211;1.22)</td><td align="left" valign="top" rowspan="1" colspan="1">1.16</td><td align="left" valign="top" rowspan="1" colspan="1">(1.03&#8211;1.30)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">High (&gt;100)</td><td align="left" valign="top" rowspan="1" colspan="1">1.36</td><td align="left" valign="top" rowspan="1" colspan="1">(1.27&#8211;1.46)</td><td align="left" valign="top" rowspan="1" colspan="1">1.21</td><td align="left" valign="top" rowspan="1" colspan="1">(1.14&#8211;1.28)</td><td align="left" valign="top" rowspan="1" colspan="1">1.10</td><td align="left" valign="top" rowspan="1" colspan="1">(1.01&#8211;1.19)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Medium (31&#8211;100)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Experience with buprenorphine prescribing</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">&lt;1</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">1&#8211;3</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">(0.83&#8211;1.01)</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">(0.88&#8211;1.06)</td><td align="left" valign="top" rowspan="1" colspan="1">1.07</td><td align="left" valign="top" rowspan="1" colspan="1">(0.96&#8211;1.18)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">&gt;3</td><td align="left" valign="top" rowspan="1" colspan="1">0.93</td><td align="left" valign="top" rowspan="1" colspan="1">(0.83&#8211;1.04)</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">(0.88&#8211;1.07)</td><td align="left" valign="top" rowspan="1" colspan="1">1.10</td><td align="left" valign="top" rowspan="1" colspan="1">(0.97&#8211;1.25)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ICC</td><td colspan="2" align="left" valign="top" rowspan="1">0.15</td><td colspan="2" align="left" valign="top" rowspan="1">0.10</td><td colspan="2" align="left" valign="top" rowspan="1">0.09</td></tr></tbody></table><table-wrap-foot id="add16684-ntgp-0004"><fn id="add16684-note-0007"><p>Abbreviations: ICC, intraclass correlation; NQF, National Quality Forum.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="add16684-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Forrest plot results from hierarchical models.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ADD-120-152-g002.jpg"/></fig><p>At the prescriber level, after adjustment for covariates, clinical training and panel size were significantly associated with patient outcomes. PCPs had a small, but statistically significant higher odds of poor medication continuity and discontinuation (poor continuity: 1.12, 95% CI = 1.02&#8211;1.23; discontinuation: 1.04, 95% CI = 1.01&#8211;1.09) for their patients compared to psychiatrists. With respect to panel size, prescribers whose panel size was greater than 100 had higher odds for the adverse outcomes in all three models (poor continuity: 1.36, 95% CI = 1.27&#8211;1.46; discontinuation: 1.21, 95% CI = 1.14&#8211;1.28; overdose: 1.10, 95% CI = 1.01&#8211;1.19), whereas prescribers with a panel size less than or equal to 30 had higher odds for discontinuation and overdose (discontinuation: 1.13, 95% CI = 1.04&#8211;1.22; overdose: 1.16, 95% CI = 1.03&#8211;1.30). For the full sample, the prescriber&#8208;level ICC values for poor medication continuity, discontinuation and opioid overdose were 0.15, 0.10 and 0.09, respectively, therefore indicating that prescribers accounted for between 9% and 15% of the variation among patients for the selected outcomes.</p><p>As noted, we conducted several sensitivity analyses. Regarding the analysis we conducted for those patients whose designated prescriber had 20 or more patients, the results were materially the same as those for the full sample including the ICC values. For the analysis that focused on fatal overdoses, results were highly comparable to those for all opioid overdoses with respect to the magnitude and significance of the odds ratios. For the analysis that focused on transitions to naltrexone, we found that ~4% of the patients who discontinued buprenorphine treatment during the study period had a prescription for this medication from within 2&#160;months of the time they discontinued. The removal of these patients from the statistical models had no impact on study findings.</p></sec><sec sec-type="discussion" id="add16684-sec-0017"><title>DISCUSSION</title><p>The results of our study indicate that both patient&#8208; and prescriber&#8208;level characteristics influence patient outcomes from buprenorphine treatment for OUD. Some patient&#8208;level results are consistent with those previously reported in the literature. Specifically, younger patients, those with a history of chronic health conditions and those with a history of substance use disorder were at greater risk for adverse outcomes [<xref rid="add16684-bib-0024" ref-type="bibr">24</xref>]. These patients likely need more support, whether through their prescriber, family or other sources of caregiving, when initiating treatment to improve their chances of a successful outcome. We also found that insurance coverage and race/ethnicity were significantly associated with patient outcomes. Patients with Medicaid coverage had considerably higher odds of adverse outcomes compared to their commercially insured counterparts. Similarly, Black, non&#8208;Hispanic and Hispanic patients were more likely to experience adverse outcomes than did White, non&#8208;Hispanic patients. These findings demonstrate that racial disparities, which have been shown to exist in the initial receipt of medication for treating OUD, are very much a concern even for patients who are able to access some degree of medication treatment [<xref rid="add16684-bib-0035" ref-type="bibr">35</xref>]. As such, the study's findings are in line with the perspective that structural racism underlies health disparities in terms of the outcomes of as well as access to treatment. Identifying strategies for improving outcomes among populations that have historically been disadvantaged by healthcare systems should be a priority for policy makers and healthcare leaders.</p><p>Our study offers new insight on the influence of prescribers relative to patient outcomes for buprenorphine treatment. We found clinical training to be associated with patient outcomes as PCPs had less favorable outcomes on average than did psychiatrists. Given the mental health issues that many patients exhibit at the time they begin buprenorphine treatment for OUD, psychiatrists may be particularly well prepared professionally to manage buprenorphine treatment. Additionally, many PCPs care for patient populations with a wide spectrum of conditions, leaving relatively less time to develop expertise for managing treatment for a condition that is as challenging as OUD. An additional possible explanation is that psychiatrists may be more selective than PCPs regarding the patients to whom they prescribe. In any event, we believe this finding warrants attention to the possible need for more training opportunities for prescribers of buprenorphine. Future research should also examine whether some prescribers are better prepared to manage buprenorphine treatment for patients with OUD who have additional mental health conditions or other comorbidities.</p><p>A strong association was also observed between prescriber panel size and patient outcomes. Patients receiving treatment from prescribers with a large panel size had higher odds of adverse outcomes. Recently, the federal government eliminated waiver requirements for prescribers so that volume thresholds no longer apply [<xref rid="add16684-bib-0036" ref-type="bibr">36</xref>]. Although our finding may raise questions about this policy decision, we note that absolute volume may not be the important consideration, but rather the resources that a prescriber has available for managing patients undergoing buprenorphine treatment. In preparation for this study, we conducted interviews with 12 prescribers in Massachusetts who were largely of the opinion that volume thresholds limit access to treatment for patients and are not a reliable predictor of a prescriber's ability to manage patients undergoing buprenorphine treatment. However, they did convey that many prescribers lack the resources needed to manage a high volume of patients because they do not have adequate support staff and digital tools such as disease registries for tracking and managing patients. Of course, provider selection effects may also be a factor underlying this finding as low&#8208;volume prescribers may be more inclined to limit their practice to patients they judge to be more likely to benefit from OUD treatment.</p><p>Certainly, these results at the prescriber level point to the influence prescribers can potentially have on patient outcomes. The opportunity for prescribers to influence patient outcomes for buprenorphine treatment is likely greatest during the early phases of treatment with respect to medication adherence. Among the selected outcome measures, the highest ICC value was for the 180&#8208;day measure of poor medication continuity, which, at 15%, is in line with other studies of clinician effects on medication adherence such as a recent investigation focusing on statin therapy [<xref rid="add16684-bib-0037" ref-type="bibr">37</xref>]. Managing patients with OUD presents unique and difficult challenges, but better short&#8208;term medication adherence may be a path to improvements in other outcomes such as opioid overdose, although this is an outcome where many other factors outside the prescribers' control can come into play.</p><p>We acknowledge several limitations of our investigation. One is the study sample, which was drawn from one state, Massachusetts. Therefore, findings may not generalize to all regions of the United States where access to prescribers of buprenorphine may vary, either higher or lower, compared to Massachusetts. Another limitation is that all individuals included in the sample had some form of health insurance. Individuals who obtain buprenorphine without insurance coverage may exhibit different outcomes than those presented in this study. A third limitation is that when constructing the study sample, we could not draw from all insured patients in Massachusetts because, as noted, the PHD is missing claims from self&#8208;insured employers who have opted out reporting to the APCD since 2016. Based on patient records included in the state prescription monitoring program (PMP) for which no corresponding insurance claims existed in the PHD, we estimate that ~6500 patients from self&#8208;insured employers would have met criteria for inclusion in the study sample, but were excluded because of the absence of insurance claims. As most of these patients would likely be commercially insured through their employer's plan, we compared their outcomes (by using PMP data) with those in the study sample who also had commercial insurance. The outcomes were generally comparable between the two groups indicating that the omission of patients from self&#8208;insured employers did not bias study findings.</p><p>Finally, as noted we were unable to track whether individuals who discontinued buprenorphine treatment did so to initiate methadone, which is a widely used medication for OUD, as the PHD does not contain complete information for all Massachusetts patients receiving methadone. As some individuals who discontinue buprenorphine treatment transition to methadone, accounting for such transitions is relevant for assessing patient outcomes following treatment discontinuation.</p></sec><sec sec-type="conclusions" id="add16684-sec-0018"><title>CONCLUSION</title><p>In this study, we sought to better understand the influence of patient&#8208;level and prescriber&#8208;level characteristics on patient outcomes for buprenorphine treatment for OUD. Although most previous research has focused on patient&#8208;level characteristics, prescribers also appear to have some level of influence on patient outcomes, particularly with respect to medication continuity during the initial 180&#8201;days of buprenorphine treatment. This presents a potential opportunity to improve longer&#8208;term outcomes. More attention should be given to assuring that prescribers who assume the responsibility of managing buprenorphine treatment for OUD have the resources they need to support patients during the treatment process.</p></sec><sec id="add16684-sec-0022"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Gary J. Young:</bold> Conceptualization (equal); formal analysis (equal); funding acquisition (lead); investigation (equal); methodology (equal); validation (equal); writing&#8212;original draft (lead). <bold>Tianjie Zhu:</bold> Conceptualization (equal); formal analysis (equal); methodology (equal); validation (equal); visualization (equal). <bold>Md Mahmudul Hasan:</bold> Conceptualization (equal); formal analysis (equal); validation (equal). <bold>Farbod Alinezhad:</bold> Conceptualization (supporting); methodology (equal); validation (supporting). <bold>Leonard D. Young:</bold> Data curation (lead); funding acquisition (supporting); investigation (equal); validation (equal). <bold>Md. Noor&#8208;E&#8208;Alam:</bold> Conceptualization (equal); formal analysis (equal); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); validation (equal).</p></sec><sec sec-type="COI-statement" id="add16684-sec-0019"><title>DECLARATION OF INTERESTS</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="add16684-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Appendix S1:</bold> Unadjusted odds ratios (without multi&#8208;level modeling).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADD-120-152-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="add16684-sec-0023"><title>ACKNOWLEDGEMENTS</title><p>The authors acknowledge and appreciate the support they received from staff at the Massachusetts Department of Public Health.</p></ack><sec sec-type="data-availability" id="add16684-sec-0021"><title>DATA AVAILABILITY STATEMENT</title><p>Data will not be available due to the confidentiality restrictions.</p></sec><ref-list id="add16684-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="add16684-bib-0001"><label>1</label><mixed-citation publication-type="book" id="add16684-cit-0002"><collab collab-type="authors">American Psychiatric Association</collab>
. <source>Opioid use disorder [Internet]</source><publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>; <year>2022</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.psychiatry.org/patients-families/opioid-use-disorder" ext-link-type="uri">https://www.psychiatry.org/patients-families/opioid-use-disorder</ext-link></mixed-citation></ref><ref id="add16684-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="add16684-cit-0003"><collab collab-type="authors">The Lancet Regional Health&#8208;Americas</collab>
. <article-title>Opioid crisis: addiction, overprescription, and insufficient primary prevention</article-title>. <source>Lancet Reg Health Am</source>. <year>2023</year>;<volume>23</volume>:<elocation-id>100557</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.lana.2023.100557</pub-id><pub-id pub-id-type="pmid">37497399</pub-id><pub-id pub-id-type="pmcid">PMC10366477</pub-id></mixed-citation></ref><ref id="add16684-bib-0003"><label>3</label><mixed-citation publication-type="book" id="add16684-cit-0004"><collab collab-type="authors">National Center for Health Statistics</collab>
. <source>Provisional drug overdose death counts</source><publisher-loc>Washington, D.C</publisher-loc>.: <publisher-name>U.S. Department of Health &amp; Human Services</publisher-name>; <year>2023</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link></mixed-citation></ref><ref id="add16684-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="add16684-cit-0005"><string-name name-style="western"><surname>Birnbaum</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Schiller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Waldman</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cleveland</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Roland</surname><given-names>CL</given-names></string-name>. <article-title>Societal costs of prescription opioid abuse, dependence, and misuse in the United States</article-title>. <source>Pain Med</source>. <year>2011</year>;<volume>12</volume>(<issue>4</issue>):<fpage>657</fpage>&#8211;<lpage>667</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4637.2011.01075.x</pub-id><pub-id pub-id-type="pmid">21392250</pub-id></mixed-citation></ref><ref id="add16684-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="add16684-cit-0006"><string-name name-style="western"><surname>Florence</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>. <article-title>The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013</article-title>. <source>Med Care</source>. <year>2016</year>;<volume>54</volume>(<issue>10</issue>):<fpage>901</fpage>&#8211;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1097/MLR.0000000000000625</pub-id><pub-id pub-id-type="pmid">27623005</pub-id><pub-id pub-id-type="pmcid">PMC5975355</pub-id></mixed-citation></ref><ref id="add16684-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="add16684-cit-0007"><string-name name-style="western"><surname>Hansen</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Oster</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Edelsberg</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Woody</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>SD</given-names></string-name>. <article-title>Economic costs of nonmedical use of prescription opioids</article-title>. <source>Clin J Pain</source>. <year>2011</year>;<volume>27</volume>(<issue>3</issue>):<fpage>194</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1097/AJP.0b013e3181ff04ca</pub-id><pub-id pub-id-type="pmid">21178601</pub-id></mixed-citation></ref><ref id="add16684-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="add16684-cit-0008"><string-name name-style="western"><surname>McAdam&#8208;Marx</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Roland</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Cleveland</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Oderda</surname><given-names>GM</given-names></string-name>. <article-title>Costs of opioid abuse and misuse determined from a Medicaid database</article-title>. <source>J Pain Palliat Care Pharmacother</source>. <year>2010</year>;<volume>24</volume>(<issue>1</issue>):<fpage>5</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.3109/15360280903544877</pub-id><pub-id pub-id-type="pmid">20345194</pub-id></mixed-citation></ref><ref id="add16684-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="add16684-cit-0009"><string-name name-style="western"><surname>Oderda</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Lake</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>R&#252;dell</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Roland</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Masters</surname><given-names>ET</given-names></string-name>. <article-title>Economic burden of prescription opioid misuse and abuse: a systematic review</article-title>. <source>J Pain Palliat Care Pharmacother</source>. <year>2015</year>;<volume>29</volume>(<issue>4</issue>):<fpage>388</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.3109/15360288.2015.1101641</pub-id><pub-id pub-id-type="pmid">26654413</pub-id></mixed-citation></ref><ref id="add16684-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="add16684-cit-0010"><string-name name-style="western"><surname>Strassels</surname><given-names>SA</given-names></string-name>. <article-title>Economic burden of prescription opioid misuse and abuse</article-title>. <source>J Manag Care Pharm</source>. <year>2009</year>;<volume>15</volume>(<issue>7</issue>):<fpage>556</fpage>&#8211;<lpage>562</lpage>. <pub-id pub-id-type="doi">10.18553/jmcp.2009.15.7.556</pub-id><pub-id pub-id-type="pmid">19739878</pub-id><pub-id pub-id-type="pmcid">PMC10437678</pub-id></mixed-citation></ref><ref id="add16684-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="add16684-cit-0011"><string-name name-style="western"><surname>White</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Birnbaum</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Mareva</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Daher</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vallow</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schein</surname><given-names>J</given-names></string-name>, et al. <article-title>Direct costs of opioid abuse in an insured population in the United States</article-title>. <source>J Manag Care Pharm</source>. <year>2005</year>;<volume>11</volume>(<issue>6</issue>):<fpage>469</fpage>&#8211;<lpage>479</lpage>. <pub-id pub-id-type="doi">10.18553/jmcp.2005.11.6.469</pub-id><pub-id pub-id-type="pmid">15998164</pub-id><pub-id pub-id-type="pmcid">PMC10437436</pub-id></mixed-citation></ref><ref id="add16684-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="add16684-cit-0012"><string-name name-style="western"><surname>Fr&#237;as</surname><given-names>&#193;</given-names></string-name>, <string-name name-style="western"><surname>Palma</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Salvador</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Aluco</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Navarro</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Farriols</surname><given-names>N</given-names></string-name>, et al. <article-title>Trends in buprenorphine prescribing for opioid use disorder by psychiatrists in the US from 2003 to 2021</article-title>. <source>Australas Psychiatry</source>. <year>2021</year>;<volume>29</volume>(<issue>3</issue>):<fpage>294</fpage>&#8211;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1177/1039856220924321</pub-id><pub-id pub-id-type="pmid">32438869</pub-id></mixed-citation></ref><ref id="add16684-bib-0012"><label>12</label><mixed-citation publication-type="book" id="add16684-cit-0013"><string-name name-style="western"><surname>Chidwick</surname><given-names>K</given-names></string-name>. <source>Buprenorphine now replaces methadone as the most common medicine for opioid dependence: 10&#8208;year trends in opioid agonist treatment medicines in Australia [internet]</source><publisher-loc>Randwick, NSW</publisher-loc>: <publisher-name>National Drug and Alcohol Research Centre</publisher-name>; <year>2024</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ndarc.med.unsw.edu.au/blog/buprenorphine-now-replaces-methadone-most-common-medicine-opioid-dependence-10-year-trends" ext-link-type="uri">https://ndarc.med.unsw.edu.au/blog/buprenorphine-now-replaces-methadone-most-common-medicine-opioid-dependence-10-year-trends</ext-link></mixed-citation></ref><ref id="add16684-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="add16684-cit-0014"><string-name name-style="western"><surname>Fatseas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Auriacombe</surname><given-names>M</given-names></string-name>. <article-title>Why buprenorphine is so successful in treating opiate addiction in France</article-title>. <source>Curr Psychiatry Rep</source>. <year>2007</year>;<volume>9</volume>(<issue>5</issue>):<fpage>358</fpage>&#8211;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1007/s11920-007-0046-2</pub-id><pub-id pub-id-type="pmid">17915074</pub-id></mixed-citation></ref><ref id="add16684-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="add16684-cit-0015"><string-name name-style="western"><surname>Chang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Daubresse</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name>. <article-title>Chronic disease medication adherence after initiation of buprenorphine for opioid use disorder</article-title>. <source>Med Care</source>. <year>2019</year>;<volume>57</volume>(<issue>9</issue>):<fpage>667</fpage>&#8211;<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1097/MLR.0000000000001165</pub-id><pub-id pub-id-type="pmid">31404013</pub-id></mixed-citation></ref><ref id="add16684-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="add16684-cit-0016"><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Bernson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Land</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xuan</surname><given-names>Z</given-names></string-name>, et al. <article-title>Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>169</volume>(<issue>3</issue>):<fpage>137</fpage>&#8211;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.7326/M17-3107</pub-id><pub-id pub-id-type="pmid">29913516</pub-id><pub-id pub-id-type="pmcid">PMC6387681</pub-id></mixed-citation></ref><ref id="add16684-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="add16684-cit-0017"><string-name name-style="western"><surname>Sordo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barrio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bravo</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Indave</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wiessing</surname><given-names>L</given-names></string-name>, et al. <article-title>Mortality risk during and after opioid substitution treatment: systematic review and meta&#8208;analysis of cohort studies</article-title>. <source>BMJ</source>. <year>2017</year>;<volume>26</volume>(<issue>357</issue>):<elocation-id>j1550</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.j1550</pub-id><pub-id pub-id-type="pmcid">PMC5421454</pub-id><pub-id pub-id-type="pmid">28446428</pub-id></mixed-citation></ref><ref id="add16684-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="add16684-cit-0018"><string-name name-style="western"><surname>Tkacz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Severt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kassed</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ruetsch</surname><given-names>C</given-names></string-name>. <article-title>Clinical differences between opioid abuse classes ameliorated after 1 year of buprenorphine&#8208;medication assisted treatment</article-title>. <source>J Addict Dis</source>. <year>2012</year>;<volume>31</volume>(<issue>2</issue>):<fpage>100</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1080/10550887.2012.665729</pub-id><pub-id pub-id-type="pmid">22540432</pub-id></mixed-citation></ref><ref id="add16684-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="add16684-cit-0019"><string-name name-style="western"><surname>Hasan</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Noor&#8208;E&#8208;Alam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>GJ</given-names></string-name>. <article-title>Long&#8208;term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>2022</year>;<volume>48</volume>(<issue>4</issue>):<fpage>481</fpage>&#8211;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1080/00952990.2022.2065638</pub-id><pub-id pub-id-type="pmid">35670828</pub-id></mixed-citation></ref><ref id="add16684-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="add16684-cit-0020"><string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>. <article-title>Impact of long&#8208;term buprenorphine treatment on adverse health care outcomes in Medicaid</article-title>. <source>Health Aff (Millwood)</source>. <year>2020</year>;<volume>39</volume>(<issue>5</issue>):<fpage>747</fpage>&#8211;<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1377/hlthaff.2019.01085</pub-id><pub-id pub-id-type="pmid">32364847</pub-id><pub-id pub-id-type="pmcid">PMC7531057</pub-id></mixed-citation></ref><ref id="add16684-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="add16684-cit-0021"><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>. <article-title>Acute care, prescription opioid use, and overdose following discontinuation of long&#8208;term buprenorphine treatment for opioid use disorder</article-title>. <source>Am J Psychiatry</source>. <year>2020</year>;<volume>177</volume>(<issue>2</issue>):<fpage>117</fpage>&#8211;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2019.19060612</pub-id><pub-id pub-id-type="pmid">31786933</pub-id><pub-id pub-id-type="pmcid">PMC7002204</pub-id></mixed-citation></ref><ref id="add16684-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="add16684-cit-0022"><string-name name-style="western"><surname>Hasan</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Noor&#8208;E&#8208;Alam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mohite</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Sasser Modestino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Peckham</surname><given-names>AM</given-names></string-name>, et al. <article-title>Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: a study of a commercially insured population in Massachusetts</article-title>. <source>J Subst Abuse Treat</source>. <year>2021</year>;<volume>131</volume>:<elocation-id>108416</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jsat.2021.108416</pub-id><pub-id pub-id-type="pmid">34098294</pub-id></mixed-citation></ref><ref id="add16684-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="add16684-cit-0023"><string-name name-style="western"><surname>Lo&#8208;Ciganic</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Gellad</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Cochran</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zemaitis</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Cathers</surname><given-names>T</given-names></string-name>, et al. <article-title>Association between trajectories of buprenorphine treatment and emergency department and in&#8208;patient utilization</article-title>. <source>Addiction</source>. <year>2016</year>;<volume>111</volume>(<issue>5</issue>):<fpage>892</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1111/add.13270</pub-id><pub-id pub-id-type="pmid">26662858</pub-id></mixed-citation></ref><ref id="add16684-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="add16684-cit-0024"><string-name name-style="western"><surname>Shcherbakova</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tereso</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Spain</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Roose</surname><given-names>RJ</given-names></string-name>. <article-title>Treatment persistence among insured patients newly starting buprenorphine/naloxone for opioid use disorder</article-title>. <source>Ann Pharmacother</source>. <year>2018</year>;<volume>52</volume>(<issue>5</issue>):<fpage>405</fpage>&#8211;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1177/1060028017751913</pub-id><pub-id pub-id-type="pmid">29302989</pub-id></mixed-citation></ref><ref id="add16684-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="add16684-cit-0025"><string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>. <article-title>Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi&#8208;state sample of Medicaid enrollees</article-title>. <source>J Subst Abuse Treat</source>. <year>2018</year>;<volume>95</volume>:<fpage>9</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2018.09.001</pub-id><pub-id pub-id-type="pmid">30352671</pub-id><pub-id pub-id-type="pmcid">PMC6354252</pub-id></mixed-citation></ref><ref id="add16684-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="add16684-cit-0026"><string-name name-style="western"><surname>Assadi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Hafezi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mokri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Razzaghi</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Ghaeli</surname><given-names>P</given-names></string-name>. <article-title>Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial</article-title>. <source>J Subst Abuse Treat</source>. <year>2004</year>;<volume>27</volume>(<issue>1</issue>):<fpage>75</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2004.05.002</pub-id><pub-id pub-id-type="pmid">15223097</pub-id></mixed-citation></ref><ref id="add16684-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="add16684-cit-0027"><string-name name-style="western"><surname>Katz</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>O'Grady</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Gandhi</surname><given-names>D</given-names></string-name>. <article-title>Transitioning opioid&#8208;dependent patients from detoxification to long&#8208;term treatment: efficacy of intensive role induction</article-title>. <source>Drug Alcohol Depend</source>. <year>2011</year>;<volume>117</volume>(<issue>1</issue>):<fpage>24</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2010.12.024</pub-id><pub-id pub-id-type="pmid">21277704</pub-id><pub-id pub-id-type="pmcid">PMC3090541</pub-id></mixed-citation></ref><ref id="add16684-bib-0027"><label>27</label><mixed-citation publication-type="book" id="add16684-cit-0028"><string-name name-style="western"><surname>Henley</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Remley</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Moyer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>White&#8208;Faines</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>S</given-names></string-name>. <source>Making measurement count: the importance of NQF</source><publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Health Affairs Forefront</publisher-name>; <year>2017</year> Availble from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.healthaffairs.org/content/forefront/making-measurement-count-importance-nqf" ext-link-type="uri">https://www.healthaffairs.org/content/forefront/making-measurement-count-importance-nqf</ext-link></mixed-citation></ref><ref id="add16684-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="add16684-cit-0029"><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Mauro</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chiodo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, et al. <article-title>Defining discontinuation for buprenorphine treatment: implications for quality measurement</article-title>. <source>Am J Psychiatry</source>. <year>2024</year>;<volume>181</volume>(<issue>5</issue>):<fpage>457</fpage>&#8211;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.20230808</pub-id><pub-id pub-id-type="pmid">38706334</pub-id><pub-id pub-id-type="pmcid">PMC11152114</pub-id></mixed-citation></ref><ref id="add16684-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="add16684-cit-0030"><string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Daubresse</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Caleb</surname><given-names>AG</given-names></string-name>. <article-title>Patterns of buprenorphine&#8208;naloxone treatment for opioid use disorder in a multistate population</article-title>. <source>Med Care</source>. <year>2017</year>;<volume>55</volume>(<issue>7</issue>):<fpage>669</fpage>&#8211;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1097/MLR.0000000000000727</pub-id><pub-id pub-id-type="pmid">28410339</pub-id><pub-id pub-id-type="pmcid">PMC6528471</pub-id></mixed-citation></ref><ref id="add16684-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="add16684-cit-0031"><string-name name-style="western"><surname>Weinstein</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Hui</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Labelle</surname><given-names>CT</given-names></string-name>, et al. <article-title>Long&#8208;term retention in office based opioid treatment with buprenorphine</article-title>. <source>J Subst Abuse Treat</source>. <year>2017</year>;<volume>74</volume>:<fpage>65</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2016.12.010</pub-id><pub-id pub-id-type="pmid">28132702</pub-id><pub-id pub-id-type="pmcid">PMC5312773</pub-id></mixed-citation></ref><ref id="add16684-bib-0031"><label>31</label><mixed-citation publication-type="book" id="add16684-cit-0032"><string-name name-style="western"><surname>Tikkanen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Osborn</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mossialos</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Djordjevic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wharton</surname><given-names>GA</given-names></string-name>. <source>United States [internet]</source><publisher-loc>New York, NY</publisher-loc>: <publisher-name>The Commonwealth Fund</publisher-name>; <year>2020</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.commonwealthfund.org/international-health-policy-center/countries/united-states" ext-link-type="uri">https://www.commonwealthfund.org/international-health-policy-center/countries/united-states</ext-link></mixed-citation></ref><ref id="add16684-bib-0032"><label>32</label><mixed-citation publication-type="book" id="add16684-cit-0033"><collab collab-type="authors">National Cancer Institute</collab>
. <source>NCI Comorbidity Index overview [Internet]. National Cancer Institute</source>. <year>2023</year>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html" ext-link-type="uri">https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html</ext-link></mixed-citation></ref><ref id="add16684-bib-0033"><label>33</label><mixed-citation publication-type="book" id="add16684-cit-0034"><collab collab-type="authors">Department of Health and Human Services</collab>
. <source>Practice guidelines for the administration of buprenorphine for treating opioid use disorder</source><publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Department of Health and Human Services</publisher-name>; <year>2021</year> (document no. 2021&#8211;08961.).</mixed-citation></ref><ref id="add16684-bib-0034"><label>34</label><mixed-citation publication-type="book" id="add16684-cit-0035"><collab collab-type="authors">Massachusetts Department of Public Health</collab>
. <source>Massachusetts public health officials release latest opioid&#8208;related overdose reports</source><publisher-name>Commonwealth of Massachusetts</publisher-name>; <year>2023</year> Availble from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://mass.gov/news/massachusetts-public-health-officials-release-latest-opioid-related-overdose-reports" ext-link-type="uri">https://mass.gov/news/massachusetts-public-health-officials-release-latest-opioid-related-overdose-reports</ext-link></mixed-citation></ref><ref id="add16684-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="add16684-cit-0036"><string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Meara</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lewinson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chun</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Onsando</surname><given-names>M</given-names></string-name>, et al. <article-title>Racial inequality in receipt of medications for opioid use disorder</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>19</issue>):<fpage>1779</fpage>&#8211;<lpage>1789</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMsa2212412</pub-id><pub-id pub-id-type="pmid">37163624</pub-id><pub-id pub-id-type="pmcid">PMC10243223</pub-id></mixed-citation></ref><ref id="add16684-bib-0036"><label>36</label><mixed-citation publication-type="book" id="add16684-cit-0037"><collab collab-type="authors">Substance Abuse and Mental Health Services Administration</collab>
. <source>Waiver elimination (MAT Act)</source><publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name>; <year>2023</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act#:~:text=Section%201262%20of%20the%20Consolidated,opioid%20use%20disorder%20(OUD" ext-link-type="uri">https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act#:~:text=Section%201262%20of%20the%20Consolidated,opioid%20use%20disorder%20(OUD</ext-link></mixed-citation></ref><ref id="add16684-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="add16684-cit-0038"><string-name name-style="western"><surname>Yao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lix</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Teare</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Blackburn</surname><given-names>DF</given-names></string-name>. <article-title>Physician influence on medication adherence, evidence from a population&#8208;based cohort</article-title>. <source>PLoS ONE</source>. <year>2022</year>;<volume>17</volume>(<issue>12</issue>):<elocation-id>e0278470</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0278470</pub-id><pub-id pub-id-type="pmid">36454907</pub-id><pub-id pub-id-type="pmcid">PMC9714848</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>